Spots Global Cancer Trial Database for Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Official Title: A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Study ID: NCT00515411
Study Description
Brief Summary: Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects. This study is being done to find out if these three drugs can be given at lower doses more often, with fewer side effects and still maintain the same benefit as the standard way of giving this three drug combination. If your tumor overexpresses a protein called Her2, you are also eligible to receive trastuzumab with chemotherapy. Trastuzumab is a medicine that has been approved by the US Food and Drug Administration for the treatment of Her2 positive breast cancer. Trastuzumab is now also a standard treatment in combination with chemotherapy for the treatment of Her2 positive stomach cancer. If your tumor is Her2 positive, you would receive the modified administration schedule of docetaxel, cisplatin, and fluorouracil with trastuzumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope Cancer Center, Duarte, California, United States
Memorial Cancer Institute, Pembroke Pines, Florida, United States
Piedmont Hospital Research Institute, Atlanta, Georgia, United States
Nebraska Cancer Specialists, Methodist Estabrook Cancer Center, Omaha, Nebraska, United States
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States
Long Island Jewish Medical Center, New Hyde Park, New York, United States
Weill Medical College of Cornell University, New York, New York, United States
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States
University Hospital of Cleveland, Cleveland, Ohio, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Yelena Janjigian, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
